ATOS · Atossa Therapeutics, Inc. · Executive Compensation
$2.45
+0.00 (+0.00%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$20.06M
Shares
9.98M
Volume · Oct 6
54.64K
Avg daily vol (3M)
74.18K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D., Ph. D. Chief Executive Officer | $2,502,856 |
| Heather Rees | CPA (Inactive) | $981,724 |
| Mark J. Daniel | — | $536,489 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D., Ph. D. Executive Officer | $2,764,082 |
| Heather Rees | CPA (inactive) | $1,149,674 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Greg Weaver | — | $2,379,426 |
| Steven Quay | M.D., Ph. D. Executive Officer | $2,356,220 |
| Kyle Guse | General Counsel and Secretary | $1,171,631 |
| Heather Rees | CPA (inactive) | $687,463 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven Quay | M.D. Ph. D. Executive Officer | $3,160,876 |
| Kyle Guse | General Counsel and Secretary | $1,527,871 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. Executive Officer | $5,892,563 |
| Kyle Guse | General Counsel and Secretary | $2,801,628 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. Executive Officer | $2,936,284 |
| Kyle Guse | General Counsel and Secretary | $1,385,466 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. President and Chief Executive Officer | $5,807,923 |
| Kyle Guse | Chief Financial Officer, General Counsel and Secretary | $2,329,472 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Steven Quay | MD., Ph.D. President and Chief Executive Officer | $2,172,344 |
| Kyle Guse | Chief Financial Officer, General Counsel and Secretary | $1,088,931 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Daniel | principal accounting officer | Appointed | 2025-10-14 |
| Mark Daniel | Chief Financial Officer | Appointed | 2025-10-14 |
| Heather Rees | Chief Financial Officer | Appointed | 2024-07-02 |
| Dr. Tessa Cigler, M.D., M.P.H. | Class II director | Appointed | 2024-03-12 |
| Jonathan Finn | Class I director | Appointed | 2023-11-09 |
| Greg Weaver | member of the Board of Directors | Resigned | 2023-10-06 |
| Greg Weaver | Executive Vice President and Chief Financial Officer | Resigned | 2023-10-06 |
| Greg Weaver | Executive Vice President and Chief Financial Officer | Appointed | 2023-06-01 |